Illumina, Inc. ($ILMN) Confident Investor Rating: Poor
| Company name | Illumina, Inc. |
| Stock ticker | ILMN |
| Live stock price | [stckqut]ILMN[/stckqut] |
| P/E compared to competitors | Fair |
| Employee productivity | Poor |
| Sales growth | Poor |
| EPS growth | Poor |
| P/E growth | Poor |
| EBIT growth | Poor |
| Confident Investor Rating | Poor |
| Target stock price (TWCA growth scenario) | $4.37 |
| Target stock price (averages with growth) | $10.97 |
| Target stock price (averages with no growth) | $18.41 |
| Target stock price (manual assumptions) | $5.92 |
The following company description is from Google Finance: http://www.google.com/finance?q=ilmn
Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations. In January 2011, the Company acquired Epicentre Technologies Corporation. In April 2010, the Company purchased Helixis, Inc.
Confident Investor comments: Unfortunately, it is difficult for a company to be profitable and still have this much red. At this price and at this time, I do not think that a Confident Investor can confidently invest in this stock.